New treatment Xadago to help 100,000 Canadians living with Parkinson’s

News

Author: Parkinson's Life editorsPublished: 5 May 2017

Prep: Cook: Serves:

More than 100,000 Canadians living with Parkinson’s will benefit from a new product to be launched in the country.

The drug known as ‘Xadago’, currently readily available in several countries across Europe, helps control motor symptoms and complications over a 24-month period.

Xadago will be the first new oral treatment for Parkinson’s in almost 15 years in Canada. On 21 March 2017 the Food and Drug Administration in the US approved the use of Xadago for the treatment of Parkinson’s as an add-on therapy to levodopa/carbidopa.

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

Fynlee Hateley: the 13-year-old Parkinson’s campaigner

The boy has raised UK £1,000 for the condition

World Parkinson Congress 2019: an Irishman in Japan

Joe Lacy shares his diary from the World Parkinson Congress 2019

Introducing the “first-ever” legislation devoted solely to ending Parkinson’s disease

Learn about the US National Plan to End Parkinson’s Act

Chemical used in dry cleaning may be associated with Parkinson’s disease

The chemical trichloroethylene (TCE) has been used across a number of industries: to decaffeinate coffee, degrease metal parts, remove stains and dry-clean clothing. It’s currently banned in the European Union and the US states New York and Minnesota, except for authorised industrial uses. Now, scientists led by Dr Ray Dorsey in the US have conducted new research claiming that TCE could be linked to an increased risk of Parkinson’s. Published in the ‘Journal of Parkinson’s Disease’, the study investigated case studies of seven people who were exposed to TCE prior to a Parkinson’s diagnosis – including basketball legend Brian Grant. The researchers “postulate that this ubiquitous chemical is contributing to the global rise of Parkinson’s and that TCE is one of its invisible and highly preventable causes”. They called for the cleaning of TCE-contaminated sites and for indoor air exposure to be diminished – as well as for further studies to be…

Could certain cancers be linked to Parkinson’s disease?

Previous research has suggested that people with Parkinson’s may generally be less likely to develop most cancers. However, a new international study has found a potential genetic link between certain types of cancer and the condition. The team analysed genetic data from genome-wide association studies – a research approach that aims to identify gene variations associated with disease risk – to recognise common genetic risk factors between cancer and Parkinson’s. The findings uncovered a genetic link between the condition and both prostate cancer and melanoma. Meanwhile, the sum of various gene variants (otherwise known as the polygenic risk score) that contribute to Parkinson’s was significantly associated with a higher risk of breast cancer. “Our results suggest the importance of shared genetic variants between Parkinson’s and some cancers,” the researchers concluded in the study, which was published in the medical journal ‘Movement Disorders’. They highlighted the need for further studies to…

Investigational Parkinson’s disease dementia therapy fails in clinical trial

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

New treatment Xadago to help 100,000 Canadians living with Parkinson’s

News

Author: Parkinson's Life editorsPublished: 5 May 2017

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

Fynlee Hateley: the 13-year-old Parkinson’s campaigner

Global update

World Parkinson Congress 2019: an Irishman in Japan

Global update

Introducing the “first-ever” legislation devoted solely to ending Parkinson’s disease

Chemical used in dry cleaning may be associated with Parkinson’s disease

Could certain cancers be linked to Parkinson’s disease?

Investigational Parkinson’s disease dementia therapy fails in clinical trial

{title}

Subscribe

New treatment Xadago to help 100,000 Canadians living with Parkinson’s

News

Author: Parkinson's Life editorsPublished: 5 May 2017

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

Fynlee Hateley: the 13-year-old Parkinson’s campaigner

Global update

World Parkinson Congress 2019: an Irishman in Japan

Global update

Introducing the “first-ever” legislation devoted solely to ending Parkinson’s disease

Chemical used in dry cleaning may be associated with Parkinson’s disease

Could certain cancers be linked to Parkinson’s disease?

Investigational Parkinson’s disease dementia therapy fails in clinical trial

{title}

Subscribe

Sign in